TEVA PHARMA INDUSTRIES LTD ADR

NYSE: TEVA (Teva Pharmaceutical Industries)

Kemas kini terakhir: 09 May, 10:51PM

16.93

-1.14 (-6.31%)

  • 1H -6.31%
  • 5H -0.06%
  • 1B 4.57%
  • 6B 1.68%
  • Tahun Ke Tarikh -20.52%
  • 1T -0.29%
  • 5T 30.03%
Penutupan Terdahulu 18.07
Buka 18.20
Jumlah Dagangan 18,702,104
Purata Dagangan (3B) 12,611,691
Modal Pasaran 20,773,617,664
Harga / Pendapatan (P/E Ke hadapan) 6.00
Harga / Jualan (P/S) 1.07
Harga / Buku (P/B) 3.29
Julat 52 Minggu
12.47 (-26%) — 22.80 (34%)
Tarikh Pendapatan 29 Jul 2025 - 4 Aug 2025
Margin Keuntungan -9.91%
Margin Operasi (TTM) 21.12%
EPS Cair (TTM) -1.45
Pertumbuhan Hasil Suku Tahunan (YOY) -5.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 317.90%
Nisbah Semasa (MRQ) 0.980
Aliran Tunai Operasi (OCF TTM) 1.25 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 2.62 B
Pulangan Atas Aset (ROA TTM) 5.09%
Pulangan Atas Ekuiti (ROE TTM) -28.30%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Menurun Bercampur
Drug Manufacturers - Specialty & Generic (Global) Menurun Bercampur
Stok Teva Pharmaceutical Industries Menurun Menaik

AISkor Stockmoo

1.1
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal -1.5
Osilator Teknikal 2.0
Purata 1.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
TEVA 21 B - - 3.29
ZTS 71 B 1.16% 28.85 16.16
TAK 48 B 1,266.49% 34.98 0.930
HLN 46 B 0.50% 24.36 2.28
RDY 11 B 54.24% 17.69 3.12
BHC 2 B - - -

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Large Value
% Dimiliki oleh Institusi 60.85%

Pemilikan

Nama Tarikh Syer Dipegang
Menora Mivtachim Holdings Ltd. 31 Dec 2024 28,381,242
Migdal Insurance & Financial Holdings Ltd. 31 Mar 2025 26,335,422
Harel Insurance Investments & Financial Services Ltd. 31 Mar 2025 22,055,547
28.2528.2523.0023.0017.7517.7512.5012.507.257.25Harga Sasaran MedianQ3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
12.47 (-26%) — 22.80 (34%)
Julat Harga Sasaran
22.00 (29%) — 25.00 (47%)
Tinggi 25.00 (Truist Securities, 47.67%) Beli
Median 23.00 (35.85%)
Rendah 22.00 (B of A Securities, 29.95%) Beli
Purata 23.33 (37.80%)
Jumlah 3 Beli
Harga Purata @ Panggilan 18.06
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Truist Securities 28 May 2025 25.00 (47.67%) Beli 18.15
JP Morgan 12 May 2025 23.00 (35.85%) Beli 17.96
B of A Securities 08 May 2025 22.00 (29.95%) Beli 18.07
06 Mar 2025 20.00 (18.13%) Beli 15.35

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
30 May 2025 Pengumuman New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
30 May 2025 Pengumuman New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
30 May 2025 Pengumuman Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS wi...
30 May 2025 Pengumuman Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS wi...
29 May 2025 Pengumuman Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
29 May 2025 Pengumuman Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
29 May 2025 Pengumuman Immuneering to Present at the Jefferies Global Healthcare Conference
27 May 2025 Pengumuman Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
27 May 2025 Pengumuman Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
27 May 2025 Pengumuman Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
27 May 2025 Pengumuman Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
22 May 2025 Pengumuman Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
22 May 2025 Pengumuman Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
20 May 2025 Pengumuman Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
20 May 2025 Pengumuman Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
20 May 2025 Pengumuman Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
20 May 2025 Pengumuman Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
19 May 2025 Pengumuman Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
19 May 2025 Pengumuman Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
19 May 2025 Pengumuman Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
19 May 2025 Pengumuman Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
15 May 2025 Pengumuman Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
15 May 2025 Pengumuman Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
12 May 2025 Pengumuman Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
12 May 2025 Pengumuman Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
07 May 2025 Pengumuman Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
07 May 2025 Pengumuman Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
07 May 2025 Pengumuman Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
07 May 2025 Pengumuman Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
05 May 2025 Pengumuman Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 Pengumuman Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 Pengumuman Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
07 Apr 2025 Pengumuman Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
07 Apr 2025 Pengumuman Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
07 Apr 2025 Pengumuman Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
02 Apr 2025 Pengumuman Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference
31 Mar 2025 Pengumuman New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
31 Mar 2025 Pengumuman New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
27 Mar 2025 Pengumuman Teva Releases Q1 2025 Aide Memoire
27 Mar 2025 Pengumuman Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
27 Mar 2025 Pengumuman Teva Releases Q1 2025 Aide Memoire
27 Mar 2025 Pengumuman Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
21 Mar 2025 Pengumuman Immuneering Corporation Announces Grant of Inducement Award
20 Mar 2025 Pengumuman Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
20 Mar 2025 Pengumuman Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
03 Mar 2025 Pengumuman Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
03 Mar 2025 Pengumuman Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
Papar semua
Purata Hasil Dividen 5T 0.00%
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
27 Nov 2017 06 Nov 2017 12 Dec 2017 0.085 Tunai
25 Aug 2017 - 14 Sep 2017 0.07225 Tunai
01 Jun 2017 - 22 Jun 2017 0.289 Tunai
28 Feb 2017 - 20 Mar 2017 0.289 Tunai
01 Dec 2016 - 20 Dec 2016 0.289 Tunai
18 Aug 2016 - 08 Sep 2016 0.289 Tunai
20 May 2016 - 07 Jun 2016 0.289 Tunai
25 Feb 2016 - 14 Mar 2016 0.289 Tunai
13 Nov 2015 - 03 Dec 2015 0.289 Tunai
18 Aug 2015 - 03 Sep 2015 0.289 Tunai
15 May 2015 - 04 Jun 2015 0.289 Tunai
17 Feb 2015 - 03 Mar 2015 0.293636 Tunai
13 Nov 2014 - 02 Dec 2014 0.269593 Tunai
19 Aug 2014 - 04 Sep 2014 0.291112 Tunai
16 May 2014 - 02 Jun 2014 0.29777 Tunai
20 Feb 2014 - 10 Mar 2014 0.293019 Tunai
18 Nov 2013 - 03 Dec 2013 0.277541 Tunai
16 Aug 2013 - 03 Sep 2013 0.273656 Tunai
16 May 2013 - 03 Jun 2013 0.268249 Tunai
19 Feb 2013 - 07 Mar 2013 0.266857 Tunai
13 Nov 2012 - 03 Dec 2012 0.202399 Tunai
13 Aug 2012 - 04 Sep 2012 0.208281 Tunai
17 May 2012 - 04 Jun 2012 0.196042 Tunai
23 Feb 2012 - 13 Mar 2012 0.197212 Tunai
10 Nov 2011 - 07 Dec 2011 0.17539 Tunai
09 Nov 2011 - 07 Dec 2011 0.171904 Tunai
04 Aug 2011 - 25 Aug 2011 0.196304 Tunai
03 Aug 2011 - 25 Aug 2011 0.199624 Tunai
19 May 2011 - 07 Jun 2011 0.199925 Tunai
10 Feb 2011 - 07 Mar 2011 0.216813 Tunai
08 Nov 2010 - 06 Dec 2010 0.173008 Tunai
02 Aug 2010 - 26 Aug 2010 0.166994 Tunai
10 May 2010 - 04 Jun 2010 0.163153 Tunai
19 Feb 2010 - 17 Mar 2010 0.164033 Tunai
06 Nov 2009 - 04 Dec 2009 0.125431 Tunai
03 Aug 2009 - 27 Aug 2009 0.124804 Tunai
08 May 2009 - 03 Jun 2009 0.120261 Tunai
23 Feb 2009 - 19 Mar 2009 0.111992 Tunai
07 Nov 2008 - 05 Dec 2008 0.09309 Tunai
01 Aug 2008 - 27 Aug 2008 0.10421 Tunai
13 May 2008 - 05 Jun 2008 0.11255 Tunai
12 May 2008 - 05 Jun 2008 0.10919 Tunai
18 Feb 2008 - 13 Mar 2008 0.10429 Tunai
15 Feb 2008 - 13 Mar 2008 0.10174 Tunai
02 Nov 2007 - 28 Nov 2007 0.084 Tunai
10 Aug 2007 - 06 Sep 2007 0.08015 Tunai
10 May 2007 - 05 Jun 2007 0.0833 Tunai
16 Feb 2007 - 15 Mar 2007 0.07866 Tunai
10 Nov 2006 - 06 Dec 2006 0.06569 Tunai
11 Aug 2006 - 08 Sep 2006 0.06434 Tunai
12 May 2006 - 07 Jun 2006 0.06257 Tunai
06 Mar 2006 - 30 Mar 2006 0.06072 Tunai
10 Nov 2005 - 07 Dec 2005 0.05188 Tunai
11 Aug 2005 - 07 Sep 2005 0.05431 Tunai
05 May 2005 - 01 Jun 2005 0.0559 Tunai
17 Feb 2005 - 17 Mar 2005 0.0559 Tunai
09 Nov 2004 - 06 Dec 2004 0.0414 Tunai
09 Aug 2004 - 07 Sep 2004 0.0401 Tunai
10 May 2004 - 07 Jun 2004 0.0768 Tunai
20 Feb 2004 - 22 Mar 2004 0.0781 Tunai
13 Nov 2003 - 12 Dec 2003 0.0587 Tunai
08 Aug 2003 - 08 Sep 2003 0.0596 Tunai
08 May 2003 - 06 Jun 2003 0.0581 Tunai
24 Feb 2003 - 24 Mar 2003 0.0546 Tunai
07 Nov 2002 - 06 Dec 2002 0.0738 Tunai
19 Aug 2002 - 16 Sep 2002 0.0738 Tunai
20 May 2002 - 17 Jun 2002 0.0701 Tunai
15 Feb 2002 - 18 Mar 2002 0.0772 Tunai
16 Nov 2001 - 17 Dec 2001 0.0531 Tunai
20 Aug 2001 - 17 Sep 2001 0.0498 Tunai
17 May 2001 - 15 Jun 2001 0.0486 Tunai
08 Mar 2001 - 06 Apr 2001 0.0477 Tunai
16 Nov 2000 - 15 Dec 2000 0.0407 Tunai
24 Aug 2000 - 21 Sep 2000 0.0415 Tunai
19 May 2000 - 19 Jun 2000 0.0405 Tunai
17 Feb 2000 - 27 Mar 2000 0.0838 Tunai
04 Nov 1999 - 30 Nov 1999 0.0529 Tunai
18 Aug 1999 - 13 Sep 1999 0.0527 Tunai
21 May 1999 - 15 Jun 1999 0.054 Tunai
08 Mar 1999 - 30 Mar 1999 0.055 Tunai
20 Nov 1998 - 11 Dec 1998 0.053 Tunai
21 Aug 1998 - 11 Sep 1998 0.058 Tunai
21 May 1998 - 22 Jun 1998 0.0639 Tunai
12 Mar 1998 - 31 Mar 1998 0.0649 Tunai
20 Nov 1997 - 09 Dec 1997 0.0666 Tunai
25 Aug 1997 - 11 Sep 1997 0.0667 Tunai
23 May 1997 - 12 Jun 1997 0.069 Tunai
07 Mar 1997 - 26 Mar 1997 0.0695 Tunai
20 Nov 1996 - 09 Dec 1996 0.0468 Tunai
26 Aug 1996 - 12 Sep 1996 0.0492 Tunai
23 May 1996 - 12 Jun 1996 0.0477 Tunai
07 Mar 1996 - 26 Mar 1996 0.0504 Tunai
20 Nov 1995 - 07 Dec 1995 0.0485 Tunai
14 Aug 1995 - 30 Aug 1995 0.0488 Tunai
17 May 1995 - 07 Jun 1995 0.051 Tunai
07 Mar 1995 - 04 Apr 1995 0.0512 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2017 0.735 4 3.88
2016 1.16 4 3.19
2015 1.16 4 1.77
2014 1.15 4 2.00
2013 1.09 4 2.71
2012 0.804 4 2.15
2011 1.16 6 2.87
2010 0.667 4 1.28
2009 0.482 4 0.86
2008 0.625 6 1.47
2007 0.326 4 0.70
2006 0.253 4 0.82
2005 0.218 4 0.51
2004 0.236 4 0.79
2003 0.231 4 0.82
2002 0.295 4 1.53
2001 0.199 4 1.29
2000 0.207 4 1.13
1999 0.215 4 2.40
1998 0.240 4 4.72
1997 0.272 4 4.60
1996 0.194 4 3.09
1995 0.200 4 3.44
Papar semua
18.5118.5117.5917.5916.6816.6815.7615.7614.8514.85May 20May 20May 21May 21May 22May 22May 23May 23May 27May 27May 28May 28May 29May 29May 30May 30

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.8000.8000.6000.6000.4000.4000.2000.2000.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda